GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 90,000 shares, a growth of 556.9% from the December 31st total of 13,700 shares. Currently, 4.6% of the company’s stock are short sold. Based on an average daily trading volume, of 365,300 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Roth Mkm assumed coverage on GT Biopharma in a research note on Monday, December 2nd. They issued a “buy” rating and a $11.00 target price on the stock. Roth Capital upgraded shares of GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd.

GT Biopharma Stock Up 0.5 %

GTBP stock opened at $2.11 on Thursday. The stock’s 50 day simple moving average is $2.68 and its 200 day simple moving average is $2.53. GT Biopharma has a 12-month low of $1.72 and a 12-month high of $10.66.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.